Lab Reference Library / Dihydrotestosterone (DHT) Hormones & Reproductive

Dihydrotestosterone (DHT)

DHT · Dihydrotestosterone · 5-alpha-Dihydrotestosterone

Reference range, optimal functional medicine levels, and why DHT is the most potent androgen in the body, how 5-alpha reductase activity determines its production from testosterone, and why monitoring DHT is essential during testosterone replacement therapy to balance androgenic benefit against BPH and hair loss risk.

Androgen MarkerTRT Monitoring

Men FM Optimal30 to 50 ng/dL

Standard Range16 to 79 ng/dL

Women ReferenceLess than 19 ng/dL

Unitsng/dL

← Back to Lab Reference Library

Category: Hormones & Reproductive | Also known as: DHT, 5-alpha-Dihydrotestosterone, 5-DHT

1. What This Test Measures

Dihydrotestosterone (DHT) is a 5-alpha-reduced metabolite of testosterone and the most potent endogenous androgen in the human body. It is produced locally in peripheral tissues, most significantly the prostate gland, liver, skin, and hair follicles, through the action of two isoforms of the enzyme 5-alpha reductase: type 1 (expressed primarily in skin and liver) and type 2 (expressed primarily in the prostate, seminal vesicles, and hair follicle dermal papilla). Approximately 4 to 9% of circulating testosterone is converted to DHT through this pathway, and the DHT produced in peripheral tissues is largely retained locally rather than re-entering systemic circulation in large quantities, making serum DHT a somewhat indirect measure of total tissue DHT exposure.

DHT binds the androgen receptor (AR) with approximately three times the affinity of testosterone and dissociates significantly more slowly, producing a far more potent androgenic signal per molecule. This receptor pharmacology explains why relatively small circulating concentrations of DHT produce profound androgenic effects: DHT is the primary driver of male external genital development during fetal life, prostate growth and secretory function across the lifespan, sebaceous gland activity and acne susceptibility, and androgen receptor-mediated hair follicle miniaturization (androgenetic alopecia) in genetically susceptible individuals.

In functional medicine, serum DHT is measured as part of comprehensive androgen panels, particularly in men on testosterone replacement therapy (TRT) where monitoring DHT tracks the degree of peripheral 5-alpha reductase activity, in men with BPH or prostate cancer history where DHT-driven prostatic stimulation is clinically relevant, and in patients with androgenetic alopecia where elevated DHT is a contributing factor. DHT is also measured in women with signs of hyperandrogenism (hirsutism, acne, alopecia) where elevated DHT may contribute to androgenic symptoms even when total testosterone is only mildly elevated.

2. Reference Range and Optimal Levels

Population	Standard Reference	FM Optimal	Interpretation
Men (adult)	16 to 79 ng/dL	30 to 50 ng/dL	Below 30: possible 5-AR deficiency, medication effect, or low total T; above 50: assess BPH, hair loss, TRT dose
Men on TRT	Varies by dose	30 to 60 ng/dL	Track alongside total T; rapid rise with scrotal application; finasteride reduces by 60 to 90%
Women (premenopausal)	Below 19 ng/dL	Below 10 ng/dL	Elevation with hirsutism, acne, or alopecia warrants PCOS and adrenal evaluation
Women (postmenopausal)	Below 15 ng/dL	Below 8 ng/dL	Very low is expected; elevation suggests persistent adrenal androgen production or exogenous androgen use

DHT values vary significantly by laboratory methodology. Gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS/MS) are the most accurate methods, particularly at low concentrations. Immunoassay-based DHT measurements have significant cross-reactivity with other steroids and are less reliable, especially in women and children where DHT concentrations are low. Specify mass spectrometry methodology when ordering for clinical decision-making.

3. 5-Alpha Reductase: The Conversion Enzyme

The clinical significance of DHT is inseparable from the activity of 5-alpha reductase (5-AR), the enzyme family that converts testosterone to DHT. 5-AR type 1 is broadly expressed in skin and liver; type 2 is the prostatic and hair follicle isoform most responsible for BPH and androgenetic alopecia. The pharmaceutical agents finasteride (5-AR type 2 selective) and dutasteride (dual 5-AR type 1 and 2 inhibitor) target these isoforms specifically.

Several factors modulate 5-AR activity beyond genetics. Insulin resistance significantly upregulates 5-AR activity, particularly in adipose tissue expressing type 1, creating a link between metabolic dysfunction and both androgenetic alopecia and BPH progression. Zinc is a natural inhibitor of 5-AR; zinc deficiency removes this inhibition and increases DHT production. Progesterone competes with testosterone for 5-AR binding, and progesterone deficiency (common in women approaching menopause) may increase DHT production from the available testosterone pool. These modifiable factors provide clinical targets for DHT reduction without pharmaceutical 5-AR inhibition.

4. DHT and Testosterone Therapy Monitoring

DHT Changes by TRT Delivery Method

Injectable testosterone (cypionate, enanthate): DHT rises proportionally with total testosterone; typical DHT on standard TRT doses (100 to 200mg weekly) reaches 40 to 70 ng/dL; conversion rate reflects individual 5-AR activity and body composition; obese patients with higher adipose 5-AR type 1 expression may convert more aggressively
Topical gels and creams (non-scrotal application): DHT production is similar to injection on a per-testosterone-unit basis; application to non-scrotal skin bypasses the high scrotal 5-AR type 2 concentration; DHT levels are predictably lower than scrotal application at equivalent total testosterone levels
Scrotal testosterone cream: scrotal skin has approximately five times the 5-AR type 2 density of other skin sites; scrotal application of testosterone cream produces DHT levels three to five times higher than equivalent non-scrotal dosing; used deliberately when clinical elevation of DHT is the therapeutic goal (libido, mood, energy via DHT-specific androgen receptor signaling)
Subcutaneous pellets: DHT trends parallel total testosterone throughout the pellet absorption cycle; rises at peak (4 to 6 weeks post-insertion) and falls toward trough (5 to 6 months); monitoring DHT at peak provides the highest-value safety checkpoint

Clinical Decisions Guided by DHT During TRT

New or worsening androgenetic alopecia: if the patient reports accelerating hair loss after starting TRT and DHT is above 60 ng/dL, options include dose reduction, switching to a lower-converting delivery method, adding low-dose finasteride (1mg daily) or topical finasteride (which limits systemic exposure), or accepting the trade-off if testosterone optimization benefits outweigh the hair loss concern
Worsening lower urinary tract symptoms (LUTS) or BPH: elevated DHT drives prostatic stromal and epithelial proliferation; if BPH symptoms worsen on TRT and DHT is elevated, adding dutasteride 0.5mg daily (which reduces both type 1 and type 2 5-AR) produces the most complete DHT suppression; alpha-blocker therapy addresses symptoms while DHT is being managed
Low DHT with sexual dysfunction on TRT: some men on TRT with adequate total testosterone but low DHT (due to polymorphisms in 5-AR type 2 or high SHBG competing with DHT binding) report persistent low libido, poor erectile function, and mood instability that responds to increasing DHT through delivery method change; scrotal application or dose adjustment may be indicated
Post-finasteride syndrome monitoring: a subset of men who discontinue finasteride after prolonged use report persistent sexual and cognitive symptoms despite DHT returning to normal; serial DHT measurement confirms hormonal normalization and separates persistent hormonal suppression from post-finasteride receptor adaptation effects

5. DHT in Women: Hyperandrogenism Evaluation

PCOS and adrenal hyperandrogenism: elevated DHT in women with hirsutism, acne, or androgenetic alopecia suggests peripheral androgen excess beyond what total testosterone alone captures; DHT elevation in PCOS reflects both increased androgen substrate and often elevated 5-AR activity from the accompanying insulin resistance; treatment targets both androgen source (via hormonal contraception or anti-androgens) and insulin resistance
Non-classical congenital adrenal hyperplasia (CAH): 21-hydroxylase deficiency causes shunting of steroidogenic precursors toward the androgen pathway; DHT can be elevated in non-classical CAH presenting in women as late-onset hirsutism and menstrual irregularity; 17-hydroxyprogesterone measurement (particularly stimulated) differentiates CAH from PCOS
5-alpha reductase excess syndromes: rare genetic conditions of enhanced 5-AR activity produce DHT elevation with normal testosterone; clinically presents as significant hirsutism and alopecia disproportionate to the total testosterone level
Exogenous androgen use: women using testosterone therapy (prescribed or non-prescribed) may have dramatically elevated DHT particularly if using formulations with high 5-AR conversion rates; monitoring DHT prevents excessive androgenic tissue exposure in women who require lower testosterone targets than men

6. How to Optimize DHT

Reduce Elevated DHT

5-AR inhibitors (pharmaceutical): finasteride 1mg daily reduces DHT by 60 to 70% (type 2 selective); dutasteride 0.5mg daily reduces DHT by 90 to 95% (dual type 1 and 2); topical finasteride (0.1% solution or compound) limits systemic exposure while providing local scalp DHT suppression; monitor for sexual side effects and ensure informed consent
Zinc supplementation (15 to 30mg daily): zinc is a natural 5-AR inhibitor; deficiency upregulates enzyme activity; repletion to serum zinc 80 to 110 mcg/dL provides measurable DHT-lowering without pharmaceutical risks; particularly relevant for men with zinc depletion from high-volume exercise or dietary inadequacy
Insulin resistance correction: adipose tissue 5-AR type 1 is upregulated by insulin and glucose excess; reducing fasting insulin through time-restricted eating, resistance training, and carbohydrate reduction lowers this conversion driver
Saw palmetto (Serenoa repens, 320mg standardized extract daily): modest 5-AR inhibitory activity; evidence strongest for BPH symptom reduction; also used for androgenetic alopecia with weaker evidence than finasteride; appropriate for patients with borderline DHT elevation preferring non-pharmaceutical approaches
Progesterone (in women): progesterone competes with testosterone at 5-AR; correcting progesterone deficiency in perimenopausal women reduces DHT production from the testosterone pool; topical or oral progesterone at physiological doses

Support Adequate DHT

Optimize total testosterone: DHT is produced from testosterone substrate; low DHT with low total testosterone requires addressing the primary testosterone deficiency first through TRT or testosterone optimization protocols before addressing DHT specifically
Reconsider 5-AR inhibitor dosing: men on finasteride or dutasteride reporting sexual dysfunction, mood changes, or fatigue may have excessive DHT suppression; serum DHT below 15 ng/dL on these medications warrants dose reduction or drug holiday to assess whether symptoms are drug-related
Delivery method optimization: men on TRT with low DHT despite adequate total testosterone who report persistent libido or mood issues may benefit from switching to scrotal testosterone cream to selectively increase DHT production through higher local 5-AR type 2 activity
Address 5-AR type 2 genetic variants: SRD5A2 gene polymorphisms reduce 5-AR type 2 activity and lower DHT conversion rate; patients with known low-activity variants may require delivery methods that favor DHT production or supplemental strategies to increase local DHT availability

Monitoring Protocol

Baseline before TRT initiation: establishes individual 5-AR conversion rate and provides the reference point for interpreting DHT changes on therapy; also identifies pre-existing DHT elevation that would increase TRT risk for BPH and hair loss
4 to 6 weeks after starting or changing TRT: captures DHT at steady state for most delivery methods; earlier for pellets (check at 4 to 6 weeks for peak level); identifies patients who are high converters before BPH or hair loss complications develop
With any dose change: DHT should be rechecked at 4 to 6 weeks after any meaningful TRT dose adjustment; proportional changes in DHT with dose confirm expected pharmacological behavior; disproportionate increases suggest 5-AR upregulation
Annually during stable TRT: once dose is optimized and DHT is in target range, annual monitoring alongside complete androgen panel (total T, free T, estradiol, SHBG, PSA) is sufficient for safety surveillance
With new BPH or hair loss symptoms: any new or worsening prostate symptoms or accelerating hair loss during TRT warrants an unscheduled DHT check before changing the treatment protocol

7. Related Lab Tests

Total TestosteronePrimary Substrate for DHT Production via 5-Alpha Reductase

→

Free TestosteroneBioavailable Androgen Fraction Alongside DHT in Androgen Assessment

→

PSADHT-Sensitive Prostatic Marker; Monitor Alongside DHT During TRT

→

SHBGBinds Both Testosterone and DHT; Modulates Free Androgen Availability

→

EstradiolAromatase Companion Pathway to 5-Alpha Reductase in Testosterone Metabolism

→

ZincNatural 5-Alpha Reductase Inhibitor; Deficiency Elevates DHT

→

8. Clinical Perspective

Clinical Perspective

DHT is the androgen that most patients on testosterone therapy have never had measured, and it is the one that most directly determines whether their therapy will produce BPH symptoms and hair loss over time. I routinely see men who have been on TRT for two or three years with no DHT monitoring whose PSA has quietly crept up and whose BPH symptoms have worsened, and when we finally check DHT it is at 75 ng/dL because they are high converters on their current delivery method and dose. The fix is often straightforward: dose reduction, delivery method change, or adding low-dose dutasteride. But none of that is possible without measuring DHT first. On the other side, I see men on finasteride for hair loss whose DHT is suppressed to 8 ng/dL who are experiencing persistent low libido, erectile dysfunction, and mood instability that resolves when we reduce the finasteride dose and allow DHT to recover to 25 or 30 ng/dL. DHT has a biological role beyond scalp hair and prostate tissue, and optimizing it requires measurement, not assumption. That is why it is in our standard androgen panel.

Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma

9. Frequently Asked Questions

What is DHT and why does it matter clinically?

DHT (dihydrotestosterone) is the most potent androgen in the human body, produced from testosterone by 5-alpha reductase in the prostate, skin, liver, and hair follicles. It binds the androgen receptor with approximately three times the affinity of testosterone and has a much slower dissociation rate, making its androgenic signal far more potent per molecule. Clinically it matters because DHT excess drives benign prostatic hyperplasia (BPH), male pattern hair loss (androgenetic alopecia), and potentially prostate cancer progression, while appropriate DHT levels are required for normal male sexual differentiation, libido, prostate health, and mood stability.

What does elevated DHT indicate?

Elevated DHT above the functional medicine optimal of 30 to 50 ng/dL in men typically indicates excessive 5-alpha reductase activity, which can be driven by insulin resistance, obesity (which upregulates 5-alpha reductase in adipose tissue), zinc deficiency (zinc normally inhibits 5-alpha reductase), and sometimes exogenous testosterone therapy at doses that push total testosterone high enough that DHT conversion increases. In men on testosterone therapy, elevated DHT alongside rapid hair loss or worsening BPH symptoms warrants dose adjustment or addition of a 5-alpha reductase inhibitor.

What does low DHT indicate?

Low DHT can reflect low total testosterone (insufficient substrate), 5-alpha reductase enzyme deficiency (a rare genetic condition), or suppression from 5-alpha reductase inhibitor medications (finasteride, dutasteride). Men taking finasteride for hair loss or dutasteride for BPH typically have DHT reduced by 60 to 90%. Persistently low DHT can impair libido, erectile function, mood, and lean body mass maintenance. In men reporting sexual side effects from 5-alpha reductase inhibitors, serial DHT measurement documents the degree of suppression.

How does DHT relate to testosterone therapy?

Exogenous testosterone is converted to DHT through 5-alpha reductase in peripheral tissues. Injectable testosterone cypionate and enanthate produce DHT levels that parallel total testosterone trends. Topical testosterone (gels, creams) applied to non-scrotal skin produces DHT levels that are proportionally similar to injection. Scrotal testosterone cream produces dramatically higher DHT levels due to the high 5-alpha reductase activity of scrotal skin, making it an option when clinical DHT elevation is specifically desired. Monitoring DHT during TRT allows dose optimization that balances therapeutic androgenic benefit against BPH and hair loss risk.

Can DHT be reduced without medications?

Yes, to a meaningful degree through several mechanisms. Zinc supplementation at 15 to 30mg daily inhibits 5-alpha reductase activity; zinc deficiency significantly upregulates the enzyme. Saw palmetto (Serenoa repens) extract has modest evidence for 5-alpha reductase inhibition and is used for both hair loss and BPH symptom management. Reducing insulin resistance lowers the adipose tissue 5-alpha reductase upregulation driven by hyperinsulinemia. Green tea catechins (EGCG) have documented 5-alpha reductase inhibitory activity in vitro and in some clinical studies. These approaches reduce DHT modestly compared to pharmaceutical inhibitors but are appropriate for patients with borderline elevation who prefer to avoid medication.

Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.

DHT is the most potent androgen in the body and the one most directly responsible for BPH and hair loss during testosterone therapy. Measuring it changes clinical decisions.

DHT monitoring is a standard component of every testosterone optimization protocol at The Lamkin Clinic. Schedule a consultation for a comprehensive androgen panel and individualized TRT management.

Schedule a Consultation

Medical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.